Patents by Inventor Olaf B. Kinstler
Olaf B. Kinstler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130189219Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: March 19, 2013Publication date: July 25, 2013Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Publication number: 20120296072Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: August 2, 2012Publication date: November 22, 2012Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 8258262Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: GrantFiled: December 16, 2009Date of Patent: September 4, 2012Assignee: Amgen Inc.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 8143380Abstract: The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers.Type: GrantFiled: July 8, 2005Date of Patent: March 27, 2012Assignee: Amgen Inc.Inventors: Kenneth W. Walker, Olaf B. Kinstler, Karen C. Sitney
-
Publication number: 20100310510Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: December 16, 2009Publication date: December 9, 2010Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 7662933Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: GrantFiled: April 26, 2006Date of Patent: February 16, 2010Assignee: Amgen Inc.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Publication number: 20080254020Abstract: The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers.Type: ApplicationFiled: July 8, 2005Publication date: October 16, 2008Applicant: AMGEN INC.Inventors: Kenneth W. Walker, Olaf B. Kinstler, Karen C. Sitney
-
Publication number: 20080206184Abstract: The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof.Type: ApplicationFiled: February 7, 2008Publication date: August 28, 2008Applicant: AMGEN INC.Inventors: Colin V. Gegg, Olaf B. Kinstler
-
Patent number: 7160924Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.Type: GrantFiled: July 18, 2003Date of Patent: January 9, 2007Assignees: The General Hospital Corporation, Amgen, Inc.Inventors: Olaf B. Kinstler, David L. Ladd, Mikahil I. Papisov
-
Patent number: 6956027Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: GrantFiled: October 4, 2002Date of Patent: October 18, 2005Assignee: Amgen Inc.Inventor: Olaf B. Kinstler
-
Publication number: 20040181035Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: March 26, 2001Publication date: September 16, 2004Applicant: Amgen, Inc.Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Publication number: 20040105840Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.Type: ApplicationFiled: July 18, 2003Publication date: June 3, 2004Inventors: Olaf B. Kinstler, David L. Ladd, Mikahil I. Papisov
-
Publication number: 20030096400Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: ApplicationFiled: October 4, 2002Publication date: May 22, 2003Applicant: Amgen, Inc.Inventor: Olaf B. Kinstler
-
Publication number: 20030053982Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: ApplicationFiled: April 25, 2002Publication date: March 20, 2003Inventor: Olaf B. Kinstler
-
Patent number: 5985265Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: GrantFiled: June 20, 1997Date of Patent: November 16, 1999Assignee: Amgen Inc.Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 5824784Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: GrantFiled: October 12, 1994Date of Patent: October 20, 1998Assignee: Amgen Inc.Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 5795569Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: October 12, 1994Date of Patent: August 18, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5766581Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. The MGDF proteins and derivatives are useful in methods for treating mammals to increase platelets and/or megakaryocytes. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: March 30, 1995Date of Patent: June 16, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5574018Abstract: Therapeutically useful proteins are conjugated to vitamin B.sub.12 by covalent binding at the primary hydroxyl site of the ribose moiety. The resulting conjugates are biologically active and can be formulated into pharmaceutical compositions suitable for delivery by various routes of administration, preferably oral. Uptake in the gut following oral delivery is further enhanced by the co-administration of purified intrinsic factor.Type: GrantFiled: July 29, 1994Date of Patent: November 12, 1996Assignee: Amgen Inc.Inventors: Alan D. Habberfield, Olaf B. Kinstler, Colin G. Pitt